Downloads: 3 | Views: 80 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Analysis Study Research Paper | Radiotherapy & Oncology | India | Volume 12 Issue 5, May 2023

Use of Geftinib and Methotrexate in Residual Cases of Squamous Cell Carcinoma of Head and Neck after Radical Treatment

Abstract: HNSCC is one of the leading cancers in India. There is very limited treatment option for residual cases of HNSCC after radical treatment. We have tried Gefitinib and methotrexate combination for residual disease after radical treatment.125 patients who have residual disease at primary site after 6 weeks of completion of radical treatment were started on gefitinib 250mg daily and methotrexate 15 mg weekly. Treatment was given for 6 months with monthly follow up and toxicity assessment. After that response to treatment was assessed. Patients with CR, PR, SD and PD are 9.3, 22.9, 30.2 and 28.1 percent respectively. So, such group of patients can be started on gefitinib and methotrexate with durable response and manageable toxicity

Keywords: Gefitinib, Methotrexate, HNSCC, Residual disease

Edition: Volume 12 Issue 5, May 2023,

Pages: 1272 - 1274